The purpose of this study is to determine the feasibility of conducting a pragmatic trial of IL-17i versus JAKi in adults with axial spondyloarthritis (axSpA) who have failed at least one tumor necrosis factor-alpha inhibitor (TNFi), to estimate the effectiveness of IL-17i versus JAKi at 16 weeks and to determine additional effectiveness measures, safety, and treatment persistence of IL-17i versus JAKi
fulfill ASAS classification criteria for axSpA and/or modified New York classification criteria for AS
Active axSpA (ASDAS ≥ 2.1 and/or BASDAI ≥ 4)
Failure of or intolerance to ≥1 TNF
Participants of reproductive potential must agree to use any form of effective contraception during the study period, in accordance with standard clinical practice and FDA labeling for the assigned study medication
Previously received an IL-17i or JAKi
Active infection requiring antimicrobials
Inflammatory bowel disease (IBD)- Crohn's disease or Ulcerative Colitis
Active cancer or cancer remission within the past 3 years (apart from non-melanoma skin cancer (NMSC) and cervical intraepithelial neoplasia (CIN)